Introduction
============

More than 5,000 years have passed since a Greek physician prescribed extracts of willow bark for musculoskeletal pain. But it was not until 1897 that Felix Hoffman synthesized acetylsalicylic acid (ASA), the first NSAID \[[@B1]\]. Nowadays, NSAIDs are among the most commonly used drugs worldwide and their analgesic, anti-inflammatory and anti-pyretic therapeutic properties are thoroughly accepted. More than 30 million people use NSAIDs every day, and they account for 60% of the US over-the-counter analgesic market \[[@B2]\]. Like many other drugs, however, NSAIDs are associated with a broad spectrum of side effects, including gastrointestinal (GI) and cardiovascular (CV) events, renal toxicity, increased blood pressure, and deterioration of congestive heart failure among others. In this review, we will focus on upper and lower GI tract injury.

Several classes of NSAIDs with different GI toxicity can be distinguished: traditional or nonselective NSAIDs (ns-NSAIDs), including high-dose ASA, which inhibit both isoforms of cyclooxygenase (COX) enzyme and are the most toxic NSAID compounds; COX-2 selective inhibitors that produce less GI damage; and new classes of NSAID, including nitric oxide NSAIDs and hydrogen sulfide-releasing NSAIDs that still are being tested in different conditions and apparently have less upper GI and CV toxicity.

Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal damage
============================================================================

The damage of gastric and duodenal mucosa caused by NSAIDs has been widely studied. These upper GI side effects include troublesome symptoms with or without mucosal injury, asymptomatic mucosal lesions, and serious complications, even death.

About 30 to 50% of NSAID users have endoscopic lesions (such as subepithelial hemorrhages, erosions, and ulcerations), mainly located in gastric antrum, and often without clinical manifestations. Generally, these lesions have no clinical significance and tend to reduce or even disappear with chronic use, probably because the mucosa is adapted to aggression \[[@B3],[@B4]\]. On the contrary, up 40% of NSAIDs users have upper GI symptoms, the most frequent being gastroesophageal reflux (regurgitation and/or heartburn) and dyspeptic symptoms (including belching, epigastric discomfort, bloating, early satiety and postprandial nausea) \[[@B3]\]. The onset of these symptoms seems to vary depending on the type of NSAID. A meta-analysis of the available trials from the Cochrane collaboration concluded that COX-2 selective inhibitor (celecoxib) was associated with less symptomatic ulcers, endoscopically detected ulcers and discontinuations for GI adverse events compared with ns-NSAIDs (naproxen, diclofenac, ibuprofen and loxoprofen) \[[@B5]\]. Unfortunately, these symptoms are not predictive of the presence of mucosal injury. Approximately 50% of patients with symptoms have no mucosal lesions; however, \>50% of users with serious peptic ulcer complications had no previous warning symptoms \[[@B3],[@B6]\].

The most important upper GI side effects are the occurrence of symptomatic and/or complicated peptic ulcer. NSAID-related upper GI complications include bleeding, perforation and obstruction. About 1 to 2% of NSAID users experienced a serious complication during treatment. Case-control studies and a meta-analysis have shown that the average relative risk (RR) of developing uncomplicated or complicated peptic ulcer is fourfold and fivefold in NSAIDs users compared with nonusers \[[@B7]-[@B9]\]. The risk is suggested to be higher during the first month of treatment (RR, 5.7; 95% confidence interval CI, 4.9 to 6.6), but remains elevated during the intake and 2 months after stopping therapy \[[@B8]\].

As we mentioned previously, in many cases the first evidence of NSAID toxicity is a GI complication. That is the main reason to say that prevention therapies should be implemented based on the presence of risk factors and not after the occurrence of dyspeptic symptoms.

Risk factors for gastrointestinal complications
-----------------------------------------------

The main risk factors for NSAID-related GI complications (Table [1](#T1){ref-type="table"}) are: older age (age ≥65 years, especially ≥70 years); prior uncomplicated or complicated ulcer; concomitant use of other drugs, including aspirin, other nonaspirin antiplatelet agents, anticoagulants, cortico-steroids or selective serotonin reuptake inhibitors; severe illness; alcohol and tobacco use; and *Heliobacter pylori*infection \[[@B10]\]. *H. pylori*infection and NSAID use have synergistic effects on risk. A meta-analysis of 16 studies showed that the odds ratio for peptic ulcer in patients with both risk factors (*H. pylori*-positive NSAID use) was 61.1 (95% CI, 9.98 to 373)), compared with *H. pylori-*negative nonusers \[[@B11]\]. Some of these risk factors can be modified. For example, two studies have showed that *H. pylori*eradication before starting NSAID therapy reduces the rate of peptic ulcer, but eradication in long-term NSAID users seems to be not effective in preventing peptic ulcer disease \[[@B12],[@B13]\].

###### 

Risk factors for nonsteroidal anti-inflammatory drug-related gastrointestinal complications

  Risk factor
  -------------------------------------------------------------------------------
  Age ≥65 years (especially \>70 years)
  History of peptic ulcer
  Use of two or more NSAIDs at the same time
  Concomitant therapy with antiplatelet agents, anticoagulants, corticosteroids
  and selective serotonin reuptake inhibitors.
  Severe illness
  *Helicobacter pylori*infection
  Use of more gastrolesive NSAIDs \[[@B14]\]
     RR of GI complications \<2: aceclofenac, ibuprofen and celecoxib
     RR of GI complications 2 to 4: rofecoxib, meloxicam, nimesulide, sulindac,
     diclofenac and ketoprofen
     RR of GI complications 4 to 5: tenoxicam, naproxen, difflunisal and
     indomethacin
     RR of GI complications \>5: piroxicam, azapropazone and ketorolaco

GI, gastrointestinal; NSAID, nonsteroidal anti-inflammatory drug; RR, relative risk.

Are NSAIDs equally harmful to the upper gastrointestinal tract?
---------------------------------------------------------------

Based on current evidence, the RR of GI bleeding is not the same with the different types of NSAIDs.

### Traditional or nonselective NSAIDs

Traditional or ns-NSAIDs, including high dose of ASA, are considered the most GI harmful kind of NSAID. GI damage is dose dependent, and slow-release formulations and drugs with longer half-life also have greater toxicity. A recent Systematic Review and Meta-Analysis of Observational Studies (the SOS Project) confirms variability in the risk of GI complications among individual NSAIDs as used in clinical practice. The RR ranged from \<2 for aceclofenac, ibuprofen and celecoxib, between 2-4 for rofecoxib, meloxicam, nimesulide, sulindac, diclofenac and ketoprofen, and between 4 to 5 for tenoxicam, naproxen, diflunisal and indomethacin, and more than 5 for piroxicam, azapropazone and ketorolac \[[@B14]\]. These differences may be attributed in part to the dose and formulations. For individual NSAIDs, data on the effect of dose and duration of use are still scant.

### Selective cyclooxygenase-2 inhibitors

The identification of the gene for the COX-2 isoenzyme in 1991 opened the door to development of NSAIDs that selectively inhibit COX-2. This isoenzyme expression can be induced by inflammatory mediators in multiples tissues and can have an important role in the mediation of pain, inflammation and fever. Selective COX-2 inhibitors inhibit this enzyme, but keep prostaglandin production via COX-1, which is involved in the maintenance of GI mucosal integrity. As a result, these drugs should in theory be safer than ns-NSAIDs for the development of upper GI complications, although COX-1 inhibition is not the only mechanism involved in GI toxicity.

A 2007 systematic review of randomized controlled trials (RCTs) showed that selective COX-2 inhibitors (celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) produced significantly fewer ulcers (RR, 0.26; 95% CI, 0.23 to 0.30) and ulcer complications (RR, 0.39; 95% CI, 0.31 to 0.50) as well as better GI tolerability compared with ns-NSAIDs \[[@B15]\]. One should keep in mind that concomitant use of low-dose ASA for CV prophylaxis is frequent among NSAID users (approximately 20 to 25% in clinical trials), mainly in older people. Evidence from subgroup analyses of the systematic review above mentioned \[[@B15]\] and several RCTs (the CLASS \[[@B16]\], TARGET \[[@B17]\] and SUCCES-1 \[[@B18]\] studies) suggests that this benefit might be reduced with the co-administration of low dose ASA. In spite of this, a meta-analysis of all available trials that include users of low-dose ASA combined with NSAIDs (traditional or selective) showed a lower GI complication risk in the group of selective COX-2 NSAID plus low-dose ASA users compared with ns-NSAID plus low-dose ASA users (RR, 0.72; 95% CI, 0.62 to 0.95) \[[@B19]\]. One should point out that these studies were nonrandomized trials and the data result from indirect comparisons.

Also of interest is a recent systematic review of RCTs that compare COX-2 inhibitors versus ns-NSAIDs plus proton pump inhibitors (PPIs) with regard to GI safety. The review involved 7,616 patients and concluded that COX-2 inhibitors reduce significantly the risk of perforation, obstruction, and bleeding (RR, 0.38; 95% CI, 0.25 to 0.56; *P*\<0.001) compared with ns-NSAIDs plus PPIs, but this benefit was significant only for high-risk and long-term users \[[@B20]\]. Selective COX-2 inhibitors are therefore as effective as ns-NSAIDs to relieve inflammation but they can reduce NSAID-associated GI toxicity. These GI benefits of selective NSAIDs have to be balanced against the known CV risk, although CV toxicity is not exclusive of selective COX-2 NSAIDs. Rofecoxib (no longer in the market), etoricoxib and diclofenac (among ns-NSAIDs) seem to have the worst CV profiles \[[@B21]\].

### New NSAIDs compounds

Nitric oxide and hydrogen sulfide are potent vasodilator molecules and increase mucosal protection, keeping its wholeness. This has led to the concept that coupling a NSAID and nitric oxide or hydrogen sulfide molecules could overcome the negative effects produced by prosta-glandin inhibition.

The nitric oxide-releasing NSAIDs, or COX-inhibiting nitric oxide donator, have been investigated as a potentially safer alternative to selective and ns-NSAIDs. Naproxcinod was the first and only COX-inhibiting nitric oxide donator investigated in clinical trials, showing a slight improvement in GI tolerability compared with naproxen. Owing to the lack of outcome studies and potential side effects not yet fully evaluated, this compound has not obtained the green light to be commercialized by official drug agencies in Europe and the USA \[[@B22]\].

NSAIDs that release hydrogen sulfide are being investigated in preclinical models.

Time trends of gastrointestinal complications and hospitalization due to them
-----------------------------------------------------------------------------

Over the past decades, there have been significant changes in the rate of hospitalizations due to GI complications. A 2004 multicenter study reported that rates of hospitalization for NSAID gastropathy first increased from 0.6% per year in 1981 to a peak of 1.5% in 1992, and then decreased to 0.5% in 2000 \[[@B23]\]. The last change could be attributed to several factors: use of lower doses of NSAIDs, an increase in less toxic NSAID and PPI use, and decreased prevalence of *H. pylori*infection.

Looking at reported time trends for hospitalizations due to GI events (overall and not only NSAID-associated GI complications), we could say that hospitalizations owing to uncomplicated peptic ulcer are decreasing over time \[[@B24],[@B25]\]. However, there were discrepancies concerning hospitalizations owing to complicated ulcers. Generally, studies that reported decreasing peptic ulcer bleeding rates were more recent and were population based. In this regard, it is interesting to highlight a Spanish study by Lanas and colleagues published in 2011 \[[@B26]\]. The authors showed that the incidence per 100,000 person-years of hospitalizations due to upper GI ulcer bleeding and perforations decreased over time (from 54.6 and 3.9 in 1996 (*R*^2^= 0.944) to 25.8 and 2.9 in 2005 (*R*^2^= 0.410), respectively). Of patients with upper GI events, 21% and 15% of patients with upper GI events were NSAID or antiplatelet users, respectively \[[@B27]\]. This tendency contrasted with a progressive and significant increase in the incidence of hospitalizations due to lower GI complications (colonic diverticular and angiodysplasia bleeding, and a small increasing trend of intestinal perforations).

Nonsteroidal anti-inflammatory drug-associated lower gastrointestinal damage
============================================================================

As we have pointed out above, the association of NSAID use with upper GI damage is well documented; however, the association with damage to the lower GI tract has not been widely studied and remains poorly characterized. NSAID-induced enteropathy has gained much attention due to the introduction of new diagnostic modalities such as capsule endoscopy (CE) and device-assisted enteroscopy, as well as the increased use of low-dose aspirin (ASA) and NSAIDs. A number of reports have suggested that NSAIDs also cause lower GI tract injury and complications. The clinical significance and frequency of adverse events with ns-NSAIDs in the lower GI tract have been increasingly reported (Table [2](#T2){ref-type="table"}).

###### 

Occurrence of main adverse effects of NSAIDs in the lower gastrointestinal tract with NSAID use

  Adverse effect               Frequency (%)
  ---------------------------- ---------------
  Increased gut permeability   44 to 70
  Gut inflammation             60 to 70
  Blood loss and anemia        30
  Malabsorption                40 to 70
  Mucosal ulceration           30 to 40

Table constructed using data from \[[@B28]\]. NSAID, nonsteroidal anti-inflammatory drug.

Epidemiology
------------

Recent publications have shown that the incidence of lower GI complications (including ulceration, bleeding, obstruction or perforation), many of them related to NSAID and ASA use, is increasing whereas the incidence of upper GI complications is decreasing \[[@B28]\] (Figure [1](#F1){ref-type="fig"}). The ratio of upper/lower complications was 4.1 in 1996 but decreased to only 1.4 in 2005 \[[@B27],[@B28]\]. Current evidence suggests that NSAIDs increase the risk of lower GI bleeding and perforation to a similar extent as that seen in the upper GI tract \[[@B29]\].

![**Time trends of gastrointestinal events**. Estimated number of events per 100,000 person-years on the basis of the adjudication of events in the validation process. Figure constructed using data from \[[@B27]\]. GI, gastrointestinal.](ar4175-1){#F1}

*Post-hoc*analysis of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) trial concluded that lower GI events accounted for 40% of all serious GI events in patients on NSAIDs \[[@B30]\]. CE studies in healthy subjects taking either short-term or long-term NSAIDs have presented evidence of mucosal damage in the small bowel. Graham and colleagues performed a CE study in arthritic patients who had been using NSAIDs for at least 3 months and showed an incidence of small intestinal mucosal injury as high as 71% \[[@B31]\]. In healthy volunteers, Maiden and colleagues reported that slow-release diclofenac use for 2 weeks resulted in macroscopic injury to the small intestine in 68 to 75% of subjects \[[@B32]\]. In addition, Goldstein and colleagues reported that 2 weeks of naproxen plus omeprazole ingestion induced small-bowel mucosal breaks in 55% of volunteers \[[@B33]\].

Growing evidence indicates that ASA can also damage the lower GI tract. A systematic review reported an increase of fecal blood loss (0.5 to 1.5 ml/day) in low-dose ASA users (\<325 mg) \[[@B34]\]. A study in healthy volunteers has shown that even enteric-coated ASA was associated with development of erosions and ulcers in 50% of volunteers \[[@B35]\]. The clinical significance of these findings is not yet clear.

Evidence suggests that COX-2 selective inhibitors are associated with fewer mucosal lesions of the small bowel than are ns-NSAIDs plus a PPI in CE studies performed in healthy subjects \[[@B36],[@B37]\]. The Celecoxib versus Omeprazole and Diclofenac in Patients with Osteoarthritis and Rheumatoid Arthritis (CONDOR) trial reported recently that the risk of clinically significant events from both the upper and lower GI tract were almost four times lower in at-risk osteoarthritis and rheumatoid arthritis patients treated with celecoxib 200 mg twice daily when compared with those receiving slow-release diclofenac 75 mg twice daily plus omepra-zole 20 mg/day \[[@B38]\].

Subclinical and clinical pictures
---------------------------------

The prevalence of NSAID-related lower GI adverse effects, including both clinical and subclinical manifestations, may exceed those detected in the upper GI tract and include a wide spectrum of lesions.

### Anemia and blood loss

In long-term NSAID users, continuous and mild blood loss produced by NSAID enteropathy may result in iron deficiency and anemia. No studies have been performed to determine the exact burden and clinical impact of this problem in patients taking NSAIDs or ASA. Furthermore, in many instances, there is no close relationship between demonstrable lesions on the upper GI tract and GI blood loss \[[@B39]\]. Morris and colleagues showed that 47% of NSAID users for rheumatoid arthritis with chronic iron deficiency anemia who had negative gastroscopy and colonoscopy findings had small-bowel ulcerations, and they concluded that this could be the reason for the development of anemia \[[@B40]\]. Moore and colleagues performed a systematic review including 1,162 subjects and found that most NSAIDs and ASA (325 mg) resulted in a small average increase in fecal blood loss of 1 to 2 ml/ day from about 0.5 ml/day at baseline \[[@B34]\]. Some individuals lost much more blood than average, 5% of those taking NSAIDs had daily blood loss ≥5 ml and 1% had dialy blood loss higher than 10 ml. For ASA at daily doses ≥1,800 mg, the rates of daily blood loss of 5 ml/day or 10 ml/day were 31% and 10%, respectively.

### Inflammation and increased permeability

The development of increased gut permeability and mucosal inflammation are the most frequent abnormalities in NSAID users \[[@B41]\]. Increased gut permeability can be seen as soon as 12 hours after the ingestion of single doses of most NSAIDs, but it is not observed in NSAIDs without enterohepatic recirculation (nabumetone, ASA) \[[@B41]-[@B44]\]. Short-term studies with COX-2 selective inhibitors have shown that these agents do not increase intestinal permeability \[[@B45],[@B46]\]. Some studies have found that NSAIDs increase fecal calprotectin in rheumatoid arthritis or osteoarthritis patients taking NSAIDs \[[@B47]\].

These tests have shown that intestinal inflammation is present in 60 to 70% of patients taking NSAIDs and that, once established, it may be detected up to 1 to 3 years after the long-term NSAID use has been stopped. Small intestine permeability is necessary for the subsequent development of small intestine inflammation, which is associated with blood and protein loss, but it is often silent \[[@B48]\].

### Mucosal ulceration

CE and enteroscopic studies have shown that NSAID use induces erythema, mucosal hemorrhage, erosions and intestinal ulceration in the small bowel, confirming previous autopsy data \[[@B49],[@B50]\]. Some reports suggest that this type of lesion can be seen in up to 40% of rheumatic NSAIDs users \[[@B31],[@B50]\]. Colonoscopy studies have also shown that NSAID intake is associated with isolated colonic ulcers, diffuse colonic ulceration that could be associated with occult bleeding, major GI bleeding and/ or perforation \[[@B51]-[@B53]\].

### Major complications

Lanas and colleagues reported in the early 1990s that 86% of patients admitted to hospital with lower GI bleeding had evidence of recent (\<7 days) NSAID or ASA use \[[@B52],[@B53]\], and a similar scenario was found later with intestinal perforation \[[@B53]\]. Recently, the presence of severe clinical side effects of the lower GI tract associated with NSAID use were confirmed by *post-hoc*analysis of different RCTs \[[@B54]-[@B56]\].

Current evidence shows contradictory results concerning the safety of COX-2 selective inhibitors because *post-hoc*analyses of the Vioxx Gastrointestinal Outcomes Research (VIGOR) and MEDAL trials have reported different results. In the VIGOR trial, lower GI events were as frequent as upper GI events, and the benefits of rofecoxib 50 mg/day over naproxen (500 mg twice daily) were present in both the upper and the lower GI tract, with a similar risk reduction of 50% and 60%, respectively \[[@B54]\]. However, in the MEDAL trial, although the incidence of lower GI events exceeded that seen in the upper GI tract (patients were advised to take PPIs if they had risk factors), there were no benefits of etoricoxib over diclofenac when looking at the incidence of lower GI complications \[[@B30]\]. CONDOR trial recently found that the risk of clinically significant outcomes throughout the entire GI tract were lower in patients treated with celecoxib 200 mg twice daily compared with those patients taking slow-release diclofenac 75 mg twice daily plus omeprazole 20 mg/day \[[@B38]\]. The authors concluded the need to review the actual preventive strategies for chronic NSAID users.

Another clinical side effect associated with NSAID use in the lower GI tract is complicated diverticular disease. A systematic review found a positive association of complicated diverticular disease with ns-NSAID use \[[@B57]\]. Wilcox and colleagues reported that the risk for lower GI bleeding among patients taking NSAIDs was 2.6 times higher compared with nonuse (95% CI, 1.7 to 3.9) \[[@B58]\]. The specific risk for diverticular bleeding was increased 3.4-fold (95% CI, 1.9 to 6.2) in NSAID users.

Nonsteroidal anti-inflammatory drug-related mortality
=====================================================

Patients developing an upper and lower GI complication are at risk of dying \[[@B59]\]. This risk is probably higher in older people \[[@B60]\] and/or in people with co-morbidities and/or with large ulcers in the posterior duodenal bulb or on the lesser curvature. The reported peptic ulcer bleeding-related mortality rates range from 5 to 12%. Most studies from the United States, Europe, and Asia place that figure closer to 5% than to 12% \[[@B27],[@B29],[@B61]\].

A recent study published by Sonnenberg looking at the time trends of ulcer disease in a representative sample of six European countries concluded that the risk of death from gastric and duodenal ulcers increased among consecutive generations born during the second half of the nineteenth century until shortly before the turn of the century and then decreased in all subsequent generations \[[@B62]\]. The increase in NSAID consumption or introduction of potent anti-secretory medications has not affected the long-term downward trends of ulcer mortality.

A recent Spanish population-based study looking at patients hospitalized because of GI adverse events between 1998 and 2006 reported that, overall, there was a statistically significant decrease in the sex-standardized and age-standardized mortality rate owing to a decrease in the number of patients hospitalized because of GI events over time \[[@B27]\]. When stratified by source, the decrease was not present in patients with lower GI events. However, the case fatality rate did not change over the study period for all types of GI complication events. One should note that the mean age of fatal cases remained constant during the study period. The authors concluded that the reduction observed in mortality associated with hospitalizations because of GI events was due to the observed decreased rate of upper GI events, probably associated with our ability to prevent those complications \[[@B15],[@B63]\]. One should also highlight that recent publications note that most peptic ulcer bleeding-related deaths are not a direct consequence of the bleeding ulcer itself. Instead, mortality derives from cardio-pulmonary conditions, multiorgan failure or terminal malignancy, suggesting that improving treatments of the bleeding ulcer may affect mortality very little \[[@B64]\].

Recognition of these associations is essential for the improvement of therapeutic strategies that focus not only on the GI tract, but also on providing supportive care and preventing complications and key-organ failure. The identification of non-GI risk factors associated with poor outcomes in peptic ulcer bleeding patients and a multidisciplinary approach for high-risk patients should help to reduce this outcome.

Key messages
============

• The presence of upper GI symptoms (dyspepsia and reflux) is not predictive of the occurrence of GI complications.

• The RR of developing serious GI complications is threefold to fivefold greater among NSAIDs user than among nonusers. The presence of risk factors is important to determine the actual risk of patients using NSAIDs.

• The most relevant upper GI risk factors are history of prior peptic ulcer, older age and concomitant use of low-dose aspirin.

• Before prescribing NSAIDs, the evaluation of both the CV and GI risk factors are mandatory.

• The risk of upper clinical significant GI events is lower for COX-2 selective inhibitor users than for those receiving ns-NSAIDs in the at-risk population.

• Over the past decade, hospitalizations due to upper GI complications have decreased, whereas the number of lower GI complications has increased.

• Current evidence suggests that NSAIDs increase the risk of lower GI bleeding and perforation to a similar extent as that seen in the upper GI tract.

• Selective COX-2 inhibitors are as effective as traditional NSAIDs to relieve inflammation.

• The COX-2 selective inhibitor celecoxib seems to be associated with lower GI mucosal damage and clinically significant events from the entire GI tract compared with ns-NSAIDs alone or those associated with omeprazole.

• Reported peptic ulcer bleeding related mortality rates range from 5 to 12% in developed countries.

• Most peptic ulcer bleeding-associated deaths are not direct sequelae of the bleeding ulcer itself. Instead, mortality derives from cardiopulmonary conditions, multiorgan failure and malignant condition.
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